
Opinion|Videos|December 19, 2025
Other Emerging TYK2 Inhibitors in Psoriasis
Panelists discuss the questions below in this video. ESK-001, another highly selective TYK2 inhibitor, has advanced into phase 3 trials in plaque psoriasis. How does its mechanism of action and emerging phase 2 data compare with deucravacitinib and zasocitinib, and what features might distinguish it within the TYK2 inhibitor class?
Advertisement
Episodes in this series

Panelists discuss the questions below in this video.
ESK-001, another highly selective TYK2 inhibitor, has advanced into phase 3 trials in plaque psoriasis. How does its mechanism of action and emerging phase 2 data compare with deucravacitinib and zasocitinib, and what features might distinguish it within the TYK2 inhibitor class?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD
2
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
3
Key Clinical Practice Pearls in Atopic Dermatitis, With Elaine Siegfried, MD
4
FAACT's “Food Allergies in the City” Offers Clinicians a Window into Patients' Daily Life
5





































































